Davis ID, et al. - Through an open-label, randomized, phase 3 trial, researchers intended to assess the improvement in survival in men with metastatic, hormone-sensitive prostate cancer when enzalutamide is added to testosterone suppression, with or without early docetaxel. Testosterone suppression and open-label enzalutamide or a standard non-steroidal anti-androgen therapy was given to 1,125 patients. Treatment discontinuation was more commonly noted in the enzalutamide group due to toxic effects, like fatigue and seizures. Yet, significantly longer progression-free and overall survival vs standard care in men with metastatic, hormone-sensitive prostate cancer receiving testosterone suppression was noted.